Report #2853319

Received Aug 8, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Unknown
Age: Age unknown
State: —
Recovered: Not recovered
Vaccinated: Jul 1, 2025
Onset: Jul 1, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	UNK	—

Symptoms (2)

Injection site warmthRash erythematous

Symptom narrative

red rash; warm injection site; This non-serious case was reported by a consumer via call center representative and described the occurrence of red rash in a patient who received Herpes zoster (Shingrix) for prophylaxis. In JUL-2025, the patient received the 2nd dose of Shingrix. In JUL-2025, less than a week after receiving Shingrix, the patient experienced red rash (Verbatim: red rash) and injection site warmth (Verbatim: warm injection site). The outcome of the red rash and injection site warmth were not resolved. It was unknown if the reporter considered the red rash and injection site warmth to be related to Shingrix. It was unknown if the company considered the red rash and injection site warmth to be related to Shingrix. Additional Information: GSK receipt date: 28-JUL-2025 The patient received 2nd Shingrix vaccine 3 days ago and now had a red rash and it was warm by the injection site. The patient asked what can he/she do to relieve this?